Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIAF
stocks logo

BIAF

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.55M
-29.65%
-2.700
-57.14%
1.48M
-19.99%
-2.400
-50%
1.70M
+33.99%
-2.100
-58.82%
Estimates Revision
The market is revising No Change the revenue expectations for bioAffinity Technologies, Inc. (BIAF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -76.01%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-76.01%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for bioAffinity Technologies Inc (BIAF.O) is -0.18, compared to its 5-year average forward P/E of -1.97. For a more detailed relative valuation and DCF analysis to assess bioAffinity Technologies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.97
Current PE
-0.18
Overvalued PE
-0.98
Undervalued PE
-2.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.99
Current PS
0.00
Overvalued PS
1.95
Undervalued PS
0.02
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BIAF News & Events

Events Timeline

(ET)
2025-10-28
09:04:26
BioAffinity Technologies Receives Approval for Australian Patent Application
select
2025-10-16 (ET)
2025-10-16
08:06:26
BioAffinity Technologies Granted Patent Approval for Algorithm
select
2025-10-15 (ET)
2025-10-15
08:07:46
BioAffinity Technologies Meets Nasdaq Compliance Requirements Again
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-03Newsfilter
bioAffinity Showcases CyPath® Lung Cancer Detection Technology with 92% Sensitivity
  • Technology Showcase: bioAffinity's Chief Medical Officer, Gordon Downie, will present at the American Cancer Society's National Lung Cancer Roundtable, highlighting CyPath® Lung's success in identifying three cases of Stage 1A lung cancer, demonstrating its effectiveness in complex cases.
  • Clinical Challenges: Faced with uncertain lung nodule diagnoses, CyPath® Lung, in conjunction with low-dose CT and PET imaging, provides clear results that assist physicians in confirming diagnoses at early stages, thereby enhancing treatment opportunities for patients.
  • Sensitivity and Accuracy: CyPath® Lung exhibits a 92% sensitivity and 88% accuracy in high-risk patients, underscoring its significance in early lung cancer detection, which can significantly improve patient survival rates.
  • Industry Collaboration: This presentation occurs at the NLCRT meeting, which includes 194 medical and public health organizations, emphasizing bioAffinity's leadership in lung cancer diagnostics and fostering collaboration and innovation within the industry.
[object Object]
Preview
7.5
11-05Newsfilter
bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume

  • Sales Growth of CyPath® Lung: bioAffinity Technologies reported a 111% increase in test volume for its noninvasive lung cancer diagnostic test, CyPath® Lung, in October 2025 compared to the monthly average for the first nine months of the year, indicating strong adoption by physicians.

  • Clinical Value Recognition: The increase in test volume reflects growing recognition among clinicians of the test's clinical value in early lung cancer detection, particularly for patients with indeterminate pulmonary nodules.

  • Consistent Growth Trends: Throughout 2025, CyPath® Lung has shown consistent month-over-month and quarter-over-quarter sales growth, with a 95% increase in third-quarter sales compared to the previous quarter.

  • Technology and Accuracy: CyPath® Lung utilizes advanced flow cytometry and AI for detecting malignancy in sputum samples, achieving 92% sensitivity and 88% accuracy in clinical studies, which underscores its potential to improve early-stage lung cancer diagnosis and patient outcomes.

[object Object]
Preview
8.5
10-10Newsfilter
bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations

  • Stock Offering Announcement: bioAffinity Technologies, Inc. has completed a registered direct offering of 720,000 shares of common stock at $2.50 per share, with proceeds intended for working capital and to support sales growth of its noninvasive lung cancer test, CyPath® Lung.

  • Company Overview: bioAffinity Technologies focuses on noninvasive cancer diagnostics, with its primary product, CyPath® Lung, demonstrating high sensitivity and accuracy for early-stage lung cancer detection, marketed through its subsidiary, Precision Pathology Laboratory Services.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is bioAffinity Technologies Inc (BIAF) stock price today?

The current price of BIAF is 1.72 USD — it has increased 9.55 % in the last trading day.

arrow icon

What is bioAffinity Technologies Inc (BIAF)'s business?

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

arrow icon

What is the price predicton of BIAF Stock?

Wall Street analysts forecast BIAF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIAF is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is bioAffinity Technologies Inc (BIAF)'s revenue for the last quarter?

bioAffinity Technologies Inc revenue for the last quarter amounts to 1.45M USD, decreased -38.48 % YoY.

arrow icon

What is bioAffinity Technologies Inc (BIAF)'s earnings per share (EPS) for the last quarter?

bioAffinity Technologies Inc. EPS for the last quarter amounts to -4.74 USD, decreased -2.07 % YoY.

arrow icon

What changes have occurred in the market's expectations for bioAffinity Technologies Inc (BIAF)'s fundamentals?

The market is revising No Change the revenue expectations for bioAffinity Technologies, Inc. (BIAF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -76.01%.
arrow icon

How many employees does bioAffinity Technologies Inc (BIAF). have?

bioAffinity Technologies Inc (BIAF) has 57 emplpoyees as of December 05 2025.

arrow icon

What is bioAffinity Technologies Inc (BIAF) market cap?

Today BIAF has the market capitalization of 7.74M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free